for the Treatment of Acute Diarrhea in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
|
Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy |
|
Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C |
|
GABAB Agonists for the Treatment of Alcohol Use Disorder. |
|
The gastrointestinal microbiome - functional interference between stomach and intestine. |
|
Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for 'gut barrier protectors' in IBD? |
|
The gut barrier: new acquisitions and therapeutic approaches |
|
Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility |
|
The Gut Microbiota and Immune System Relationship in Human Graft-versus-Host Disease |
|
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease |
|
Gut microbiota in autism and mood disorders |
|
Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin |
|
Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy |
|
Helicobacter pylori in metabolic related diseases. |
|
Helicobacter pylori infection contributes to placental impairment in preeclampsia: basic and clinical evidences. |
|
Helicobacters and extragastric diseases |
|
Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival |
|
HepPar1-Positive Circulating Microparticles Are Increased in Subjects with Hepatocellular Carcinoma and Predict Early Recurrence after Liver Resection |
|
High prevalence of Cag-A positive H. pylori strains in ischemic stroke: a primary care multicenter study |
|
High prevalence of celiac disease in patients with lactose intolerance |
|
The human gut microbiota and virome: Potential therapeutic implications |
|
The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center |
|
Impact of the Trophic Effects of the Secretome From a Multistrain Probiotic Preparation on the Intestinal Epithelia |
|
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network |
|
Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? |
|
Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation |
|
The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease |
|
Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells |
|
Letter to the Editor: Winter is coming and COVID-19 vaccine is available! The role of gastroenterologist in increasing COVID-19 vaccine acceptability among IBD patients |
|
Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth |
|
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice. |
|
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer |
|
Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study |
|
Management and treatment of lactose malabsorption |
|
May Gender or Ethnicity Affect Delta Over Baseline Values Obtained by 13-C Urea Breath Test? |
|
The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease |
|
[Microbiota and inflammatory bowel disease: an update.] |
|
Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study |
|
A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn's disease patients |
|
Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for inflammatory bowel disease treatment |
|
Monofocal hepatocellular carcinoma: how much does size matter? |
|
A multicentre case control study on complicated coeliac disease: two different patterns of natural history, two different prognoses |
|
Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease |
|
New semiquantitative ultrasonographic score for peripheral arterial disease assessment and its association with cardiovascular risk factors |
|
Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome? |
|
Nutrients affecting gastric barrier |
|
Origin of celiac disease: how old are predisposing haplotypes? |
|
Palaeodiet reconstruction in a woman with probable celiac disease: a stable isotope analysis of bone remains from the archaeological site of Cosa (Italy). |
|
Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate |
|
Prophylactic aspirin therapy does not increase faecal calprotectin concentrations |
|
Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases |
|
Proteobacteria: A Common Factor in Human Diseases. |
|
Quantitative evaluation of liver function by the methionine and aminopyrine breath tests in the early stages of liver transplantation |
|
Quick test: a new test for the diagnosis of duodenal hypolactasia |
|
Real life experiences in HCV management in 2018 |
|
Regional cerebral hypoperfusion in patients with celiac disease. |
|
Regorafenib: a promising treatment for hepatocellular carcinoma |
|
Regression of lactose malabsorption in coeliac patients after receiving a gluten-free diet |
|
Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. |
|
Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study |
|
Risk factors for gastric cancer: is it time to discard PPIs? |
|
Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update |
|
The role of methane in intestinal diseases |
|
Role of microbiota and innate immunity in recurrent Clostridium difficile infection. |
|
Role of probiotics in patients with Helicobacter pylori infection |
|
Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use. |
|
Sarilumab use in severe SARS-CoV-2 pneumonia |
|
Small Intestinal Bacterial Overgrowth Affects the Responsiveness to Colchicine in Familial Mediterranean Fever. |
|
Subclinical atherosclerosis is linked to small intestinal bacterial overgrowth via vitamin K2-dependent mechanisms |
|
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients |
|
TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib |
|
The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications |
|
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. |
|
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. |
|
ToF-SIMS and principal component analysis of lipids and amino acids from inflamed and dysplastic human colonic mucosa |
|
Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila |
|
Transradial versus Transfemoral Access for Hepatic Chemoembolization: Intrapatient Prospective Single-Center Study |
|
Treatment of early stage chronic hepatitis C virus infection. |
|
The use of probiotics in different phases of diverticular disease. |
|
The use of single balloon enteroscopy in Crohn's disease and its impact on clinical outcome |
|
Usefulness of contrast-enhanced ultrasound (CEUS) in Inflammatory Bowel Disease (IBD) |
|
What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective |
|
Zolpidem high-dose abuse: what about the liver? Results from a series of 107 patients |
|